Sargent Bickham Lagudis LLC Lyell Immunopharma, Inc. Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 1,000 shares of LYEL stock, worth $16,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$16,930% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
9Shares Held
37.4MCall Options Held
0Put Options Held
0-
Apoletto LTD Washington, DC15.1MShares$256 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$228 Million0.0% of portfolio
-
Wu Xi App Tec Co., Ltd. Shanghai, F47.39MShares$125 Million53.56% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL641KShares$10.9 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA595KShares$10.1 Million1.69% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $4.2B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...